Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and PLD in BRCA Wild-type Platinum-resistant Ovarian Cancer
NCT03509246Phase 2Unknown
- Sponsor
- Seoul National University Hospital
- Start
- May 2018
- Primary completion
- Mar 2022
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Seoul National University Hospital. Status: unknown.
02
Drugs
bortezomib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03509246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03509246.